The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer

被引：11

作者：

Alonso, Salvador ^{[1
]}

Saltz, Leonard ^{[1
,2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[2] Weill Cornell Med, Dept Med, New York, NY USA

来源：

ANNALS OF SURGICAL ONCOLOGY | 2021年 / 28卷 / 02期

关键词：

METASTATIC COLORECTAL-CANCER; OXALIPLATIN-BASED CHEMOTHERAPY; FLUOROURACIL PLUS LEUCOVORIN; MISMATCH REPAIR STATUS; STAGE-II; ADJUVANT CHEMOTHERAPY; PHASE-III; 1ST-LINE TREATMENT; THERAPY; SURVIVAL;

D O I：

10.1245/s10434-020-09375-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Micrometastatic disease that is present at the time of surgery is responsible for the overwhelming majority of deaths in patients with what is otherwise perceived to be local and regional colon cancer. The goal of perioperative therapy is to eliminate microscopic residual disease that would otherwise be left behind following surgery. A secondary goal specific to neoadjuvant (preoperative) therapy is to downstage tumors deemed potentially not amenable to an R0 resection on the basis of a suspected T4b primary (locally invading into a surrounding structure). In this landmark series paper, we review the current standard for perioperative therapy in patients with colon cancer.

引用

页码：995 / 1001

页数：7

共 41 条

[1] Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial [J].

Alberts, Steven R. ;

Sargent, Daniel J. ;

Nair, Suresh ;

Mahoney, Michelle R. ;

Mooney, Margaret ;

Thibodeau, Stephen N. ;

Smyrk, Thomas C. ;

Sinicrope, Frank A. ;

Chan, Emily ;

Gill, Sharlene ;

Kahlenberg, Morton S. ;

Shields, Anthony F. ;

Quesenberry, James T. ;

Webb, Thomas A. ;

Farr, Gist H., Jr. ;

Pockaj, Barbara A. ;

Grothey, Axel ;

Goldberg, Richard M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (13) :1383-1393

[2] Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Petrelli, Nicholas J. ;

Colangelo, Linda H. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

Goldberg, Richard M. ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Lopa, Samia ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16

[3] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[4] Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study [J].

Andre, Thierry ;

de Gramont, Armand ;

Vernerey, Dewi ;

Chibaudel, Benoist ;

Bonnetain, Franck ;

Tijeras-Raballand, Annemilai ;

Scriva, Aurelie ;

Hickish, Tamas ;

Tabernero, Josep ;

Van Laethem, Jean Luc ;

Banzi, Maria ;

Maartense, Eduard ;

Shmueli, Einat ;

Carlsson, Goran U. ;

Scheithauer, Werner ;

Papamichael, Demetris ;

Moeehler, Marcus ;

Landolfi, Stefania ;

Demetter, Pieter ;

Colote, Soudhir ;

Tournigand, Christophe ;

Louvet, Christophe ;

Duval, Alex ;

Flejou, Jean-Francois ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) :4176-+

[5] American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].

Benson, AB ;

Schrag, D ;

Somerfield, MR ;

Cohen, AM ;

Figueredo, AT ;

Flynn, PJ ;

Krzyzanowska, MK ;

Maroun, J ;

McAllister, P ;

Van Cutsem, E ;

Brouwers, M ;

Charette, M ;

Haller, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419

[6] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[7] Adjuvant Chemotherapy Is Associated With Improved Survival in Patients With Stage II Colon Cancer [J].

Casadaban, Leigh ;

Rauscher, Garth ;

Aklilu, Mebea ;

Villenes, Dana ;

Freels, Sally ;

Maker, Ajay V. .

CANCER, 2016, 122 (21) :3277-3287

[8] First-line chemotherapy for mCRC-a review and evidence-based algorithm [J].

Cremolini, Chiara ;

Schirripa, Marta ;

Antoniotti, Carlotta ;

Moretto, Roberto ;

Salvatore, Lisa ;

Masi, Gianluca ;

Falcone, Alfredo ;

Loupakis, Fotios .

NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (10) :607-619

[9] Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial [J].

de Gramont, Aimery ;

Van Cutsem, Eric ;

Schmoll, Hans-Joachim ;

Tabernero, Josep ;

Clarke, Stephen ;

Moore, Malcolm J. ;

Cunningham, David ;

Cartwright, Thomas H. ;

Hecht, J. Randolph ;

Rivera, Fernando ;

Im, Seock-Ah ;

Bodoky, Gyoergy ;

Salazar, Ramon ;

Maindrault-Goebel, Frederique ;

Shacham-Shmueli, Einat ;

Bajetta, Emilio ;

Makrutzki, Martina ;

Shang, Aijing ;

Andre, Thierry ;

Hoff, Paulo M. .

LANCET ONCOLOGY, 2012, 13 (12) :1225-1233

[10] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

← 1 2 3 4 5 →